CVRx initiated with an Overweight at JPMorgan » 08:5607/2607/26/21
JPMorgan analyst Robbie…
JPMorgan analyst Robbie Marcus initiated coverage of CVRx with an Overweight rating and $24 price target. The company has developed the Barostim NEO system for a segment of heart failure patients who currently have very limited treatment options, Marcus tells investors in a research note. The analyst says CVRx's "differentiated offering and unique positioning" should enable a "clear pathway for growth and multiple years of beat-and-raise potential."
CVRx initiated with a Buy at Canaccord » 07:2807/2607/26/21
Canaccord analyst William…
Canaccord analyst William Plovanic initiated coverage of CVRx with a Buy rating and $30 price target. The analyst believes they are uniquely positioned in addressing significant unmet needs in the cardiovascular market through BARISTIM technology. The technology provides a significant quality of life improvement to HFrEF patients who remain symptomatic despite medical therapy and who do not qualify for CRT treatment.
CVRx initiated with an Outperform at William Blair » 07:0507/2607/26/21
William Blair analyst…
William Blair analyst Margaret Kaczor initiated coverage of CVRx with an Outperform rating and no price target. CVRx's Barostim is one of the only medical devices approved for symptom relief in patients with advanced heart failure with reduced ejection fraction, "filling a critical unmet need for a life debilitating disease," Kaczor tells investors in a research note. The analyst expects "strong demand" and an over 100% growth rate annually over the next three-plus years.
CVRx initiated with an Overweight at Piper Sandler » 05:0607/2607/26/21
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien initiated coverage of CVRx with an Overweight rating and $26 price target. The company is known for its BAROSTIM technology to treat patients with chronic heart failure with key benefits being improved quality of life and fewer hospitalizations, O'Brien tells investors in a research note. With potential expanded indications and new applications for the technology on the horizon, the addressable market for CVRx could expand significantly over the coming years, says the analyst. He encourages exposure at current share levels.
|Over a week ago|
Opening Day: Zoom Video rival Kaltura rises in market debut » 07:5307/2407/24/21
GAMB, ZM, CRBU, OB, SOPH, XPOF, CNM, CTKB, USCB, RYAN, ABSI, BASE, ZENV, ZVIA, INST, KLTR, LAW, PYCR, VTEX, TCBC, HCWB, VEEE, HEPS, DIDI, DNUT, EVCM, WAVE, CURV, ABOS, VRAR, IAS, CVRX, RCRT, S, XMTR, INTA, LZ, YOU, AVTE, HOOD, QNIU, CMSL, SPRK, SCAN, DUOL, AUTH, RXST, SNPO, BLK, SPG, MS, GS, BCS, BAC
Zoom Video's (ZM) rival…
CVRx appoints Martha Shadan to board of directors » 08:2507/1207/12/21
CVRx announces the…
CVRx announces the addition of Martha Shadan to the company's board of directors. She currently serves as the president and CEO of Miach Orthopaedics, a developer of bioengineered surgical implants for connective tissue repair. Shadan is actively involved with the Advanced Medical Technology Association, serving on the Board of Directors since 2017, and as a member of the Accel Board of Directors, a division of AdvaMed.
Opening Day: DiDi pops, then drops, after anticipated debut » 07:5807/0307/03/21
DIDI, HEPS, DNUT, EVCM, WAVE, CURV, ABOS, VRAR, IAS, CVRX, RCRT, S, XMTR, INTA, LZ, CPOP, YOU, AVTE, DDL, JANX, TASK, BZ, MNDY, LFST, ZETA, DIBS, ATY, ALZN, HOOD, QNIU, RGCB, CMSL, SPRK, BLND, SCAN, VTEX, GAMB, DUOL
Despite a below-guided…
|Over a month ago|
CVRx opens at $26.25, IPO priced at $18 » 13:1106/3006/30/21
The deal size was…
The deal size was increased to 7M shares from 6.3M shares and priced above the $15.00-$17.00 range. JPMorgan, Piper Sandler and William Blair acted as joint book running managers for the offering. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing neuromodulation solutions for patients with cardiovascular diseases. The shares are trading on the Nasdaq under the ticker symbol "CVRX."
CVRx 7M share IPO priced at $18.00 » 08:0106/3006/30/21
The correct pricing is…
The correct pricing is $18.00. The deal size was increased to 7M shares from 6.3M shares and priced above the $15.00-$17.00 range. JPMorgan, Piper Sandler and William Blair acted as joint book running managers for the offering.